Choose a channel
Check out the different Progress in Mind content channels.
Progress in Mind
Welcome to Progress in Mind’s live coverage of ECNP 2021. This 34th Congress of the European College of Neuropsychopharmacology – Lisbon 2021 ended today, October 5th, with presentations and lively discussion on the importance of early intervention, especially for adolescents; key findings in the neurobiology of and mechanisms behind a number of psychiatric conditions; cannabinoids and serotonin psychedelics as treatment strategies and our latest understandings regarding the etiology and treatment of migraine. Here is a summary of today’s (Day 4) highlights from this the closing day of the conference.
Neurobiology, social media and autism biomarkers
Today’s “Campfire Sessions” discussed:
Genetic testing may aid psychiatric diagnosis but there are issues involved in its use
Today’s Brainstorming sessions highlighted:
Novel therapeutic targets and treatments
Symposia included:
Astrocytes play a key role in neuronal function
Professor Edward Bullmore’s Plenary Lecture looked at how new understandings of the role of inflammation in depression may help guide the development of new treatments and therapy strategies.
The Brain Prize Plenary Lecture was delivered by Professor Jes Olesen and focussed on his group’s work on the genetics and molecular mechanisms of migraine and how prophylactic treatment is helping people with this sometimes debilitating condition.
Advances in the understanding of migraine can steer novel treatment
Other interesting sessions included the latest developments on music therapy for neuropsychiatric disorders; how best to deliver essential early intervention strategies for young people with obsessive-compulsive disorder; how evidence-based practice needs to be used to help people with ADHD throughout their life; and what we know about ‘Imposter syndrome’.
Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.
1. AIMS-2-Trial. https://www.aims-2-trials.eu.
2. Abu-Hassan, K.; Taylor, J. D.; Morris, P. G.; Donati, E.; Bortolotto, Z. A.; Indiveri, G.; Paton, J. F. R.; Nogaret, A. Optimal solid state neurons. Nat Commun 2019, 10, 5309.
3. Ceraso, A.; Lin, J. J.; Schneider-Thoma, J.; Siafis, S.; Tardy, M.; Komossa, K.; Heres, S.; Kissling, W.; Davis, J. M.; Leucht, S. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2020.
4. Preller, K. H.; Duerler, P.; Burt, J. B.; Ji, J. L.; Adkinson, B.; Stämpfli, P.; Seifritz, E.; Repovš, G.; Krystal, J. H.; Murray, J. D.; Anticevic, A.; Vollenweider, F. X. Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. Biological Psychiatry 2020, 88, 197-207.
5. McCarthy, M. J. Missing a beat: assessment of circadian rhythm abnormalities in bipolar disorder in the genomic era. Psychiatr Genet 2019, 29, 29-36.